Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 12:47 AM ET


Company Overview of Lycera Corp.

Company Overview

Lycera Corp., a biopharmaceutical company, discovers and develops oral immune modulators for the treatment of patients with autoimmune diseases and cancers. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.

2800 Plymouth Road


Building 26

Ann Arbor, MI 48109

United States

Founded in 2006



Key Executives for Lycera Corp.

Chief Executive Officer, President and Director
Age: 56
Co-Founder, Chief Scientific Officer and Director
Chief Financial Officer
Senior Vice President of Corporate Development and Strategy
Compensation as of Fiscal Year 2015.

Lycera Corp. Key Developments

Lycera Corp. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:00 PM

Lycera Corp. Presents at Boston Biotech Conferences 2015, Nov-12-2015 02:00 PM. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States.

Lycera Corp Appoints Alex G. Howarth as Chief Financial Officer

Lycera Corp. announced the appointment of Alex G. Howarth as Chief Financial Officer. With over 25 years of experience in healthcare and financial advisory roles, Mr. Howarth brings to Lycera a distinguished track record in the industry. He will be responsible for all finance-related activities for the Company, including accounting, financial planning, and strategic analysis. Mr. Howarth will report directly to Paul Sekhri, Lycera's President and CEO, and his appointment is effective immediately. Prior to joining Lycera Corp., Mr. Howarth most recently served as Executive Vice President and Chief Financial Officer of moksha8.

Lycera and Celgene Partner to Advance Development of Immune Modulators

Lycera has entered an exclusive strategic collaboration with Celgene to advance the development of its proprietary pipeline for cancer and immune-mediated diseases. The partnership will advance development of Lycera's novel pipeline, including first-in-class RORgamma agonists for cancer immunotherapy and clinical-stage candidate, LYC-30937, being studied for inflammatory bowel disease (IBD). As part of the deal, Lycera will provide an $82.5 million upfront cash payment, which comprises an exclusive option for Celgene to license Lycera's portfolio of ex-vivo RORgamma agonist compounds. The deal will also allow Lycera to receive near term payments of an additional $22.5 million associated with the ex-vivo licensing option rights. In addition, the deal provides Celgene exclusive rights to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones.

Similar Private Companies By Industry

Company Name Region
Professional Packaging Corp. United States
Celltech Manufacturing, Inc. United States
QOL Medical, LLC United States
Plasmogen Inc. United States
Jenner Technologies Inc United States

Recent Private Companies Transactions

Private Placement
June 12, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Lycera Corp., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at